Eiji Kikuchi

Dr. Eiji Kikuchi

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2009 in Cancer
Verified
Journal Article
Open access
PDF file
VMVitaly Margulis
Vitaly Margulis
SSShahrokh F. Shariat
Shahrokh F. Shariat
SMSurena F. Matin
Surena F. Matin
AKAshish M. Kamat
Ashish M. Kamat
RZRichard Zigeuner
Richard Zigeuner
TCthe Upper Tract Urothelial Carcinoma Collaboration
the Upper Tract Urothelial Carcinoma Collaboration
BACKGROUND: The literature on upper tract urothelial carcinoma (UTUC) has been limited to small, single center studies. A large series of patients treated with radical nephroureterectomy for UTUC were studied, and variables associated with poor prognosis were identified.METHODS: Data on 1363 patients treated with radical nephroureterectomy at 12 academic centers were collected. All pathologic slides were re‐reviewed by genitourinary pathologists according to strict criteria.RESULTS: Pathologic review revealed renal pelvis location (64%), necrosis (21.6%), lymphovascular invasion (LVI) (24.8%), concomitant carcinoma in situ (28.7%), and high‐grade disease (63.7%). A total of 590 patients (43.3%) underwent concurrent, lymphadenectomy and 135 (9.9%) were lymph node (LN) ‐positive. Over a mean follow‐up of 51 months, 379 (28%) patients experienced disease recurrence outside of the bladder and 313 (23%) died of UTUC. The 5‐year recurrence‐free and cancer‐specific survival probabilities (±SD) were 69% ± 1% and 73% ± 1%, respectively. On multivariate analysis, high tumor grade (hazards ratio [HR]: 2.0, P < .001), advancing pathologic T stage (P‐for‐trend <.001), LN metastases (HR: 1.8, P < .001), infiltrative growth pattern (HR: 1.5, P < .001), and LVI (HR: 1.2, P = .041) were associated with disease recurrence. Similarly, patient age (HR: 1.1, P = .001), high tumor grade (HR: 1.7, P = .001), increasing pathologic T stage (P‐for‐trend <.001), LN metastases (HR: 1.7, P < .001), sessile architecture (HR: 1.5, P = .002), and LVI (HR: 1.4, P = .02) were independently associated with cancer‐specific survival.CONCLUSIONS: Radical nephroureterectomy provided durable local control and cancer‐specific survival in patients with localized UTUC. Pathologic tumor grade, T stage, LN status, tumor architecture, and LVI were important prognostic variables associated with oncologic outcomes, which could potentially be used to select patients for adjuvant systemic therapy. Cancer 2009. © 2009 American Cancer Society.

7 September 2016 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
FSFrancesco Soria
Francesco Soria
SSShahrokh F. Shariat
Shahrokh F. Shariat
SLSeth P. Lerner
Seth P. Lerner
HFHans-Martin Fritsche
Hans-Martin Fritsche
MRMichael Rink
Michael Rink
GTGeorge N. Thalmann
George N. Thalmann

1 February 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EKEiji Kikuchi
Eiji Kikuchi
VMVitaly Margulis
Vitaly Margulis
PKPierre I. Karakiewicz
Pierre I. Karakiewicz
Marco RoscignoMarco Roscigno
Marco Roscigno
SMShuji Mikami
Shuji Mikami
SSShahrokh F. Shariat
Shahrokh F. Shariat
Purpose: To assess the association of lymphovascular invasion (LVI) with cancer recurrence and survival in a large international series of patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Patients and Methods: Data were collected on 1,453 patients treated with RNU at 13 academic centers and combined into a relational database. Pathologic slides were rereviewed by genitourinary pathologists according to strict criteria. LVI was defined as presence of tumor cells within an endothelium-lined space. Results: LVI was observed in 349 patients (24%). Proportion of LVI increased with advancing tumor stage, high tumor grade, presence of tumor necrosis, sessile tumor architecture, and presence of lymph node metastasis (all P < .001). LVI was an independent predictor of disease recurrence and survival (P < .001 for both). Addition of LVI to the base model (comprising pathologic stage, grade, and lymph node status) marginally improved its predictive accuracy for both disease recurrence and survival (1.1%, P = .03; and 1.7%, P < .001, respectively). In patients with negative lymph nodes and those in whom a lymphadenectomy was not performed (n = 1,313), addition of LVI to the base model improved the predictive accuracy of the base model for both disease recurrence and survival by 3% (P < .001 for both). In contrast, LVI was not associated with disease recurrence or survival in node-positive patients (n = 140). Conclusion: LVI was an independent predictor of clinical outcomes in nonmetastatic patients who underwent RNU for UTUC. Assessment of LVI may help identify patients who could benefit from multimodal therapy after RNU. After confirmation, LVI should be included in staging of UTUC.

1 April 2012 in European Urology
Verified
Journal Article
Closed access
ECEugene K. Cha
Eugene K. Cha
SSShahrokh F. Shariat
Shahrokh F. Shariat
MKMatthias Kormaksson
Matthias Kormaksson
GNGiacomo Novara
Giacomo Novara
TCThomas F. Chromecki
Thomas F. Chromecki
VMVitaly Margulis
Vitaly Margulis

1 February 2012 in European Urology
Verified
Journal Article
Closed access
TCThomas F. Chromecki
Thomas F. Chromecki
ECEugene K. Cha
Eugene K. Cha
HFHarun Fajkovic
Harun Fajkovic
VMVitaly Margulis
Vitaly Margulis
GNGiacomo Novara
Giacomo Novara
SSShahrokh F. Shariat
Shahrokh F. Shariat

1 June 2009 in Journal of Urology
Verified
Journal Article
Closed access
Marco RoscignoMarco Roscigno
Marco Roscigno
SSShahrokh F. Shariat
Shahrokh F. Shariat
VMVitaly Margulis
Vitaly Margulis
PKPierre Karakiewicz
Pierre Karakiewicz
MRMesut Remzi
Mesut Remzi
FMFrancesco Montorsi
Francesco Montorsi
We examined the impact of lymphadenectomy on the clinical outcomes of patients with upper tract urothelial cancer treated with radical nephroureterectomy. Data were collected on 1,130 consecutive patients with pT1-4 upper tract urothelial cancer treated with radical nephroureterectomy at 13 centers worldwide. Patients were grouped according to nodal status (pN0 vs pNx vs pN+). The choice to perform lymphadenectomy was determined by the treating surgeon. All pathology slides were reevaluated by dedicated genitourinary pathologists. Univariable and multivariable Cox regression models measured the association of nodal status (pN0 vs pNx vs pN+) with cancer specific survival. Overall 412 patients (36.5%) had pN0 disease, 578 had pNx disease (51.1%) and 140 had pN+ disease (12.4%). The 5-year cancer specific survival estimate was lower in patients with pN+ compared to those with pNx disease (35% vs 69%, p <0.001), which in turn was lower than that in those with pN0 disease (69% vs 77%, p = 0.024). In the subgroup of patients with pT1 disease (345) cancer specific survival rates were not different in those with pN0 and pNx. In pT2-4 cases (813) cancer specific survival estimates were lowest in pN+, intermediate in pNx and highest in pN0 (33% vs 58% vs 70%, p = 0.017). When adjusted for the effects of standard clinicopathological features pN+ was an independent predictor of cancer specific survival (p <0.001). pNx was significantly associated with worse prognosis than pN0 in pT2-4 upper tract urothelial cancer only. Nodal status is a significant predictor of cancer specific survival in upper tract urothelial cancer. pNx is significantly associated with a worse prognosis than pN0 in pT2-4 tumors. Patients expected to have pT2-4 disease should undergo lymphadenectomy to improve staging and thereby help guide decision making regarding adjuvant chemotherapy.